Johnson & Johnson submitted its single-shot COVID-19 vaccine to U.S. regulators recently for emergency use authorization after the vaccine was shown to be effective against illness and preventing severe disease and death.
Johnson & Johnson submitted its single-shot COVID-19 vaccine to U.S. regulators recently for emergency use authorization after the vaccine was shown to be effective against illness and preventing severe disease and death.
According to a statement by Paul Stoffels, chief scientific officer of Johnson & Johnson, the submission is “a pivotal step toward reducing the burden of disease for people globally and putting an end to the pandemic.”
If the vaccine is approved by the FDA, it would be the third authorized shot in the U.S. FDA officials announced outside experts would discuss the vaccine at a public meeting February 26.
The company announced its vaccine was 66% effective overall at preventing moderate to severe illness in a global clinical trial in a release last week. It also said J&J's vaccine offered the best protection against severe cases of disease, proving 85% effective.
Stoffels added the company would be ready to ship doses immediately upon authorization but did not specify the number. In a report by the Washington Post, government officials told them doses could be in the single-digit millions.
It's also been reported the J&J vaccine can be stored at refrigerator temperatures for several months.
In the meantime to approval, the FDA said it will propose draft guidelines on how manufacturers of COVID-19 vaccines, therapeutics and diagnostic tests should deal with new variants of the virus.
Janet Woodcock, the FDA’s acting commissioner, pledged to pursue streamlined processes to get updated products to health-care personnel. She said the FDA would not “create obstacles” to authorizing tools that could be useful.
Woodcock said in a statement that the FDA has anticipated the emergence of variants and does not believe there will be “the need to start at square one with any of these products.”
Muthiah “Muthu” Vaduganathan Discusses the Role of SGLT2 Inhibitors in Heart Failure Treatment
March 27th 2024Editors of Managed Healthcare Executive spoke with Muthiah “Muthu” Vaduganathan MD, MPH, consultant cardiologist at Brigham and Women's Hospital and a member of faculty at Harvard Medical School, about the evolving treatment landscape for heart failure, emphasizing the use of SGLT2 inhibitors alongside other foundational therapies.
Read More
In this second part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein spoke with CeCi Connolly and Margaret "Meg" Murray about Medicare Advantage utilization and challenges, highlighting proposed CMS payment cuts and prior authorization issues.
Listen
With aging populations, osteoporosis rates are set to increase, and researchers are looking for the next innovative drug to help prevent or manage the bone disease as there is currently no drug that completely does so effectively, according to a recent study published in Advanced Science.
Read More
In this first part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein kicks off our new podcast series "DC Roundtable," with guests Margaret "Meg" Murray, CEO of the Association of Community Affiliated Plans, and member of MHE's Editorial Advisory Board, and CeCi Connolly, president and CEO of the Alliance of Community Health Plans, for a discussion on healthcare policy issues.
Listen
2024 Emerging Leaders in Healthcare — Submit For a Chance to Be Featured in MHE's August Issue
March 26th 2024MHE Editors are seeking diverse healthcare professionals from different backgrounds and healthcare sectors, with individual interests. Eligible candidates are early or mid-career leaders with less than 10 years of experience. Award winners will enjoy complimentary passes to the PBMI Annual National Meeting in Orlando, Florida, from Sept. 4-6. Additional perks include a feature in our August issue, a subscription to MHE and more!
Read More